Sep, 2024

U.S.A.
News / Therapeutic Area News
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
- Eight abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio and two lead pipeline programs across a broad range of cancer types - TOKYO, Sept....
Read More

Aug, 2024

U.S.A.
News / Therapeutic Area News
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
- First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1 - European Marketing Authorization...
Read More
U.S.A.
News / Therapeutic Area News
China's National Medical Products Administration (NMPA) Approves PADCEV™ (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer
- Approval based on the global EV-301 and China EV-203 trials, where enfortumab vedotin significantly improved overall survival (OS) and objective response rate (ORR) respectively in patients...
Read More

Jul, 2024

U.S.A.
News / Therapeutic Area News
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union - A decision on the EU marketing authorization is...
Read More
U.S.A.
News / Therapeutic Area News
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care...
Read More